Influenza is a respiratory illness caused by influenza A and B viruses. Avian flu (also sometimes called bird flu) is a type of influenza caused by the H5N1 influenza virus and is known to infect mainly birds. Although it can infect other animals, including humans, it does not usually spread easily from person to person.
Why are we doing the study?
We will compare the immune response and safety of two doses of a Health Canada approved avian influenza vaccine (Arepanrix™) given at a 3-week interval compared to an 8-week interval between doses. The results will help provide information to help in public health decision making about how best to use this vaccine.
Who can participate?
You may be able to join the study if you are in stable health, 18 to 59 years of age, and not pregnant or breastfeeding.
What does the study involve?
Participants will be randomly assigned to receive two doses of the approved H5N1 Vaccine (Arepanrix™) at either a 3-week or 8-week interval, plus one dose of a placebo vaccine (saline injection). Participation will involve six in-person visits at the VEC and three phone calls over 12 months. The total time commitment of the study is about 5-5.5 hours.
We will perform a screening (general health and medical history check) at the first visit, provide the vaccine or placebo at the first, second, and third visits, and we will collect a blood sample and ask questions about your health at all visits.
How do I sign up for this study?
If you are interested in this study, please call us at (604) 875-2187 or email us (vecstudies@bcchr.ubc.ca).